HEP 001: A prospective, open label, multicenter, partially randomised, safety study of one cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) paediatric patients (Coordination)
Cliniques Universitaires UCL de Saint Luc - UCLStLuc